COX Nicox SA

Number of voting rights as of May 6, 2020

Number of voting rights as of May 6, 2020

Nicox SA

Société anonyme with a registered capital of € 33,469,770

Head Office:

DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis 

R.C.S. GRASSE 403.942.642

On May 6, 2020,

MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS

(Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF)

 As of May 6, 2020
Total number of shares composing the share capital33,469,770
Total number of voting rights33,469,770
Total number of voting rights, calculated based on the total number of shares, including the shares deprived of voting rights33,469,770

---------------



Phone: 00

Fax : +33  4-97-24-53-99

 

Attachment

EN
06/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nicox SA

 PRESS RELEASE

Nicox Completes NCX 470 New Drug Application Key Data Generation for S...

Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026 Press Release Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026 All clinical trial and long-term stability data required for the preparation of the New Drug Applications (NDA) has been generated and analysedPre-NDA meeting1 with the U.S. Food and Drug Administration (FDA) in preparation; U.S. NDA submission on-track as planned in H1 2026 Submission of NDA in China similarly on track for 2026 December 16, 2025 – release at 7:30 am CETSophia...

 PRESS RELEASE

Nicox finalise la génération des données clés de demande d’autorisatio...

Nicox finalise la génération des données clés de demande d’autorisation de mise sur le marché de NCX 470 pour un dépôt maintenu au premier semestre 2026 Communiqué de presseNicox finalise la génération des données clés de demande d’autorisation de mise sur le marché de NCX 470 pour un dépôt maintenu au premier semestre 2026 Toutes les données d’ essais cliniques et de stabilité à long terme requises pour la préparation des demandes d’autorisation de mise sur le marché (NDA), ont été générées et analyséesRéunion pré-NDA1 avec la Food and Drug Administration (FDA) américaine en préparation ; ...

 PRESS RELEASE

Nicox Provides First Half 2025 Financial Results

Nicox Provides First Half 2025 Financial Results Press Release Nicox Provides First Half 2025 Financial Results  New Drug Application (NDA) submissions for NCX 470 expected in 2026 in the U.S. and ChinaCompany believes that it can finance its existing operations for at least 12 months and expects to fully repay existing financial debts in 2026 October 23, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided the financial results for Nicox SA (the “Company”) for the first half of 2...

 PRESS RELEASE

Nicox : Résultats financiers du premier semestre 2025

Nicox : Résultats financiers du premier semestre 2025 Communiqué de presseNicox : Résultats financiers du premier semestre 2025  Les dépôts de demande d’autorisation de mise sur le marché (NDA) pour NCX 470 sont attendues en 2026 pour les Etats-Unis et la ChineLa Société estime qu’elle peut financer ses opérations pendant au moins 12 mois et prévoit de rembourser intégralement ses dettes financières existantes en 2026 23 octobre 2025 – publication à 7H30Sophia Antipolis, FranceNicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée ...

 PRESS RELEASE

Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in D...

Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Press Release Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Additional pre-planned analysis of the NCX 470 Denali trial completed NCX 470 maintains robust intraocular pressure lowering at 6, 9 and 12 monthsOther analyses broadly in line with the trends seen for Mont BlancData presentations planned for upcoming ophthalmology conferences October 2, 2025 – release at 7:30 am CETSophia Antipo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch